CM
MCRB icon

Caption Management’s Seres Therapeutics MCRB Stock Holding History

Caption Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-381
Closed -$18.1K – 1533
2023
Q3 		$18.1K Buy
+381
New +$29.1K ﹤0.01% 1217
2021
Q4 		– Sell
-163
Closed -$23K – 1803
2021
Q3 		$23K Sell
163
-2,984
-95% -$584K ﹤0.01% 1445
2021
Q2 		$1.5M Buy
+3,147
New +$1.33M 0.02% 784
2020
Q3 		– Sell
-2,000
Closed -$665K – 1175
2020
Q2 		$191K Buy
+2,000
New +$175K 0.01% 798

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caption Management's MCRB Position: Q4 2023 in Review

Caption Management sold out of Seres Therapeutics (MCRB) in Q4 2023, closing a stake of 381 shares — an estimated $18.1K sold.

Caption Management first reported a position in MCRB in Q2 2020 and held it in 4 quarters. The position peaked at $1.5M in Q2 2021. 102 funds tracked by Wall St. Rank hold MCRB as of Q4 2023.

  • Caption Management reported no remaining Seres Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Caption Management sold 381 Seres Therapeutics shares in Q4 2023, an estimated $18.1K.
  • Caption Management first reported a position in Seres Therapeutics in Q2 2020 and held it in 4 quarters.
  • Caption Management's Seres Therapeutics position peaked at $1.5M in Q2 2021.
  • 102 funds tracked by Wall St. Rank held Seres Therapeutics as of Q4 2023.

Based on Caption Management's 13F filing for Q4 2023, filed 14 Feb 2024.